Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-10-31

FDA Approved: LEVOTHYROXINE SODIUM — Supplemental Application (Accord Healthcare Inc.)

View source ↗

Summary

FDA approved a supplemental application for levothyroxine sodium from Accord Healthcare Inc. under an ANDA.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • LEVOTHYROXINE SODIUM (levothyroxine sodium)

Snippet

SUPPL AP for LEVOTHYROXINE SODIUM (LEVOTHYROXINE SODIUM)